Key Points
- CEO Dan Paterson sold 2,000 shares on Dec. 10 at an average price of $10.07 and has been disposing of multiple small blocks across Nov–Dec, leaving him with 412,818 shares (a 0.48% decline) valued at about $4.16M.
- Verastem shares traded at $9.61 midday with a market cap of $641.8M, a negative P/E of −2.38, a 52‑week range of $3.45–$11.24, and 50/200‑day moving averages of $9.17/$7.77.
- The company recently missed quarterly EPS (−$1.35 vs. −$0.51 expected), while analysts hold a consensus Moderate Buy rating and a $14.29 price target.
Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of the company's stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $10.07, for a total transaction of $20,140.00. Following the transaction, the chief executive officer owned 412,818 shares of the company's stock, valued at $4,157,077.26. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Dan Paterson also recently made the following trade(s):
- On Monday, December 8th, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.50, for a total transaction of $21,000.00.
- On Friday, December 5th, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.61, for a total transaction of $21,220.00.
- On Wednesday, December 3rd, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.00, for a total transaction of $20,000.00.
- On Monday, December 1st, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.39, for a total value of $20,780.00.
- On Friday, November 28th, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.79, for a total value of $21,580.00.
- On Wednesday, November 26th, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.32, for a total value of $20,640.00.
- On Monday, November 24th, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.00, for a total value of $20,000.00.
- On Friday, November 21st, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.00, for a total value of $20,000.00.
- On Monday, November 3rd, Dan Paterson sold 3,299 shares of Verastem stock. The stock was sold at an average price of $9.74, for a total value of $32,132.26.
- On Tuesday, September 16th, Dan Paterson sold 390 shares of Verastem stock. The shares were sold at an average price of $9.99, for a total value of $3,896.10.
Verastem Stock Performance
Shares of NASDAQ VSTM traded up $0.18 during midday trading on Friday, reaching $9.61. 1,609,260 shares of the company traded hands, compared to its average volume of 2,155,050. The company has a market cap of $641.76 million, a price-to-earnings ratio of -2.38 and a beta of 0.41. The stock has a 50-day moving average price of $9.17 and a 200 day moving average price of $7.77. Verastem, Inc. has a 52 week low of $3.45 and a 52 week high of $11.24. The company has a debt-to-equity ratio of 2.06, a current ratio of 2.58 and a quick ratio of 2.55.
Verastem (NASDAQ:VSTM - Get Free Report) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.84). The business had revenue of $11.24 million for the quarter, compared to analysts' expectations of $5.76 million. Sell-side analysts anticipate that Verastem, Inc. will post -3.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Verastem
Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in Verastem by 182.9% during the third quarter. Russell Investments Group Ltd. now owns 4,578 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 2,960 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Verastem during the second quarter valued at approximately $49,000. Nebula Research & Development LLC purchased a new stake in shares of Verastem in the 2nd quarter valued at approximately $53,000. The Manufacturers Life Insurance Company lifted its position in shares of Verastem by 9.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 1,440 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Verastem by 110.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,550 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 4,496 shares during the period. Hedge funds and other institutional investors own 88.37% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently commented on VSTM. Zacks Research cut Verastem from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 18th. BTIG Research reiterated a "buy" rating and set a $20.00 price target on shares of Verastem in a research report on Tuesday, September 9th. HC Wainwright reissued a "buy" rating and issued a $14.00 price objective on shares of Verastem in a research note on Tuesday, October 21st. Royal Bank Of Canada set a $13.00 target price on Verastem and gave the company an "outperform" rating in a research note on Monday, October 20th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Verastem in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Verastem has a consensus rating of "Moderate Buy" and a consensus price target of $14.29.
Check Out Our Latest Research Report on VSTM
About Verastem
(
Get Free Report)
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
